Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBEF), a biopharmaceutical firm developing innovative medicines for rare diseases, told investors it is exploring strategic alternatives to improve shareholder value. The company said that among the alternatives it has been considering are uplisting opportunities, for example, listing on the Australian Securities Exchange or the New York Stock Exchange.
Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBEF) has announced that Wesley Ramjeet will join its Board of Directors in the coming months. Ramjeet, who is the chief executive and Founder of PPMT Strategic Group, brings over two decades of strategic financial expertise to the biopharmaceutical company.
Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBEF) has announced the appointment of Dr Frederick Sancilio to its board of directors. The company, which is focused on developing transformative medicines targeting rare diseases, highlighted that Dr Sancilio brings more than four decades of experience in pharmaceutical sciences and biopharmaceutical research to the position.
28 Apr 2025 Date | | - Cons. EPS | - EPS |
18 Feb 2025 Date | | - Cons. EPS | - EPS |
30 Jul 2024 Date | | - Cons. EPS | - EPS |
26 Jul 2024 Date | | - Cons. EPS | - EPS |
29 Apr 2024 Date | | - Cons. EPS | - EPS |
28 Apr 2025 Date | | - Cons. EPS | - EPS |
18 Feb 2025 Date | | - Cons. EPS | - EPS |
30 Jul 2024 Date | | - Cons. EPS | - EPS |
26 Jul 2024 Date | | - Cons. EPS | - EPS |
29 Apr 2024 Date | | - Cons. EPS | - EPS |
Drug Manufacturers - Specialty & Generic Industry | Healthcare Sector | Dr. Frederick Dominick Sancilio M.S., Ph.D. CEO | OTC PINK Exchange | CA53946V2066 ISIN |
CA Country | - Employees | - Last Dividend | 10 Jun 2022 Last Split | - IPO Date |
Lobe Sciences Ltd. is a pioneering biopharmaceutical entity dedicated to harnessing the potential of proprietary psychedelic substances with the aim of advancing brain health, mental wellness, and overall cognitive function. The company operates at the forefront of a burgeoning field of medicine that seeks to leverage sub-hallucinogenic dosages of psychedelic compounds to address a variety of neurological and psychiatric conditions. Initially known as Greenstar Biosciences Corp., the organization underwent a significant rebranding in November 2020, emerging as Lobe Sciences Ltd., to better reflect its focused mission and expanding research endeavors. With its headquarters firmly established in Vancouver, Canada, Lobe Sciences Ltd. represents a blend of innovative research and steadfast dedication to finding novel solutions within the health and wellness landscape.
At the core of Lobe Sciences Ltd.'s operations is its intensive research and development efforts surrounding psychedelic substances. These endeavors are targeted at uncovering and harnessing the therapeutic potential of sub-hallucinatory doses of these compounds. The ultimate goal is to develop treatments that can significantly improve mental health outcomes, enhance cognitive abilities, and foster an overall state of wellness in individuals facing neurological and psychiatric challenges.